ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
The Burden of Antimicrobial Resistant Bacteremia in Ontario: A Population-Wide Analysis of Attributable Mortality From 110 Pathogen-Antibiotic Combinations.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundReliable information on the burden of antimicrobial resistance (AMR) is necessary to confront the threat of antimicrobial resistance. We sought to examine the association between AMR and mortality across cultured bacterial bloodstream pathogens in the province of Ontario, Canada.
methodsWe used linked microbiology data from 114 hospital, community, and public health laboratories to develop a positive bacterial blood culture episode cohort, between January 2017 and December 2021, for the population of Ontario, Canada (population 14.6 million). Antibiotics tested in >10% of cultures of a pathogen, with resistance 1%-99%, were eligible. We used separate proportional hazards models for each pathogen, to estimate the hazard ratio of 30-day mortality for each eligible antibiotic, adjusting for patient risk factors, and summarized results using mixed-effects meta-analysis.
resultsWe identified 83 962 bacteremia episodes, due to 30 pathogens, and 110 eligible pathogen-antibiotic combinations. The 30-day mortality was 17.1% (14 362/83 962). Unadjusted associations between resistance and 30-day mortality were substantially larger (hazard ratio [HR] = 1.47; 95% confidence interval [CI], 1.32-1.65) than adjusted associations accounting for age, sex, healthcare exposures, comorbidities, and co-resistance (HR = 1.10; 95% CI, 1.07-1.16). Associations were larger for antibiotics commonly used for empiric treatment (HR = 1.18; 95% CI, 1.10-1.26).
conclusionsWe found that antimicrobial resistance was associated with a 10% relative increase in the risk of mortality among patients with bacteremia, and 1.2 AMR attributable deaths per 100 000 population per year in Ontario, Canada. Comprehensive risk adjustment is necessary for understanding the impact of AMR bacteremia on patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.